Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1649 1675
This examiner grants 61% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17843812 | ANTI-TGF-BETA ANTIBODY FORMULATIONS AND THEIR USE | Non-Final OA | Genzyme Corporation |
| 17771353 | CRIZANLIZUMAB CONTAINING ANTIBODY FORMULATIONS | Final Rejection | NOVARTIS AG |
| 17609261 | ANTI-CD40 ANTIBODIES FOR USE IN TREATMENT OF TIDM AND INSULITIS | Final Rejection | NOVARTIS AG |
| 17512751 | Anti-IL-6 Antibody Formulation | Non-Final OA | Novo Nordisk A/S |
| 17775520 | DOSING REGIMEN FOR ANTI-DLL3 AGENTS | Final Rejection | AMGEN INC. |
| 17759792 | PH-SENSITIVE FC VARIANTS | Non-Final OA | Korea University Research and Business Foundation |
| 18043562 | LAG-3 ANTAGONIST THERAPY FOR HEPATOCELLULAR CARCINOMA | Non-Final OA | Bristol-Myers Squibb Company |
| 17629161 | ANTIBODY AGAINST THE OPRF PROTEIN OF PSEUDOMONAS AERUGINOSA, USE THEREOF AS A MEDICAMENT AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | Final Rejection | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE |
| 17635111 | CHIMERIC ANTIGEN RECEPTORS FOR TREATING MYELOID MALIGNANCIES | Non-Final OA | Regents of the University of Minnesota |
| 17755604 | ANTI IL-33 THERAPEUTIC AGENT FOR TREATING RENAL DISORDERS | Final Rejection | MedImmune Limited |
| 18173680 | Compositions and Methods for Killing PD-1 Positive Cells | Non-Final OA | University of Utah Research Foundation |
| 18141116 | LYM-1 AND LYM-2 ANTIBODY COMPOSITIONS AND IMPROVED CAR CONSTRUCTS | Non-Final OA | University of Southern California |
| 18328410 | TREATMENTS FOR HERMANSKY-PUDLAK SYNDROME | Non-Final OA | Acceleron Pharma Inc. |
| 17616941 | TUMOR-ASSOCIATED ANTIGEN-SPECIFIC T CELL RESPONSES | Final Rejection | Oregon Health & Science University |
| 17798025 | ANTIGEN-BINDING MOLECULES AGAINST ALPPL2 AND/OR ALPP AND USES THEREOF | Final Rejection | Agency for Science, Technology and Research |
| 18060129 | Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent | Final Rejection | OSE IMMUNOTHERAPEUTICS |
| 18020656 | ONE-ARMED ANTIGEN-BINDING MOLECULES AND USES THEREOF | Non-Final OA | Chugai Seiyaku Kabushiki Kaisha |
| 17257745 | LUCIFERASE VARIANT | Final Rejection | Kikkoman Corporation |
| 18011807 | DOSAGE AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) IN PEDIATRIC PATIENTS | Non-Final OA | Alexion Pharmaceuticals, Inc. |
| 17788330 | ANTI-CTLA-4 MONOCLONAL ANTIBODY, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Final Rejection | Bio-Thera Solutions, Ltd. |
| 17259800 | METHODS OF USING PHARMACOLOGIC INHIBITORS OF TYPE 2 CYTOKINE SIGNALING TO TREAT OR PREVENT PANCREATIC CANCER | Final Rejection | Memorial Sloan Kettering Cancer Center |
| 17906660 | HIGH CONCENTRATION ANTI-Abeta PROTOFIBRIL ANTIBODY FORMULATIONS AND METHODS OF USE THEREOF | Final Rejection | Eisai R&D Management Co., Ltd. |
| 18246516 | NOVEL ANTI-CLAUDIN18 ANTIBODIES | Non-Final OA | ELPISCIENCE BIOPHARMA, LTD. |
| 17596183 | Anti-CEACAM5 monoclonal antibody and preparation method thereof and use thereof | Non-Final OA | BIOTHEUS INC. |
| 17796418 | ANTI-TRANSFERRIN RECEPTOR (TFR) ANTIBODY AND USES THEREOF | Non-Final OA | Dyne Therapeutics, Inc. |
| 17861176 | ANTIBODY CONJUGATES AND MANUFACTURE THEREOF | Non-Final OA | Bright Peak Therapeutics AG |
| 18002010 | CONDITIONALLY ACTIVE ANTI-CD46 ANTIBODIES, ANTIBODY FRAGMENTS, THEIR IMMUNOCONJUGATES AND USES THEREOF | Non-Final OA | BIOATLA, INC. |
| 18000533 | AGONIST ANTI-CD40 ANTIBODIES | Non-Final OA | Selvax Pty Ltd |
| 17916067 | TUMOR ANTIGENS FOR LIVER CANCER IMMUNOTHERAPY | Final Rejection | ISTITUTO NAZIONALE TUMORI IRCCS - FONDAZIONE G. PASCALE |
| 17912091 | BIOMARKER PANELS, SYSTEMS, AND METHODS FOR RISK STRATIFICATION OF A SUBJECT FOR ALZHEIMER'S DISEASE | Non-Final OA | URVOGELBIO PRIVATE LIMITED |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy